PMID-36240893 – KPV Smart-Release Film for Diabetic Wound Healing
Zhao Y, et al. Skin-adaptive film with KPV-loaded smart-release microneedles for diabetic wound healing. Int J Biol Macromol. 2022;213:1028-1038.
Quick Reference
| Property | Value |
|---|---|
| PMID | 36240893 |
| DOI | 10.1016/j.ijbiomac.2022.10.054 |
| Year | 2022 |
| Journal | International Journal of Biological Macromolecules |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Diabetic rat wound model |
| Peptide(s) Studied | KPV |
Key Findings
- A skin-adaptive film incorporating KPV-loaded smart-release microneedles was engineered for sustained delivery to diabetic wounds
- KPV-loaded films significantly accelerated wound closure rates compared to controls in diabetic rat models
- The delivery system provided controlled, sustained release of KPV at the wound site, overcoming the rapid degradation typical of small peptides
- KPV reduced local inflammatory markers and promoted the transition from inflammatory to proliferative wound healing phases
- The microneedle approach enhanced KPV penetration into wound tissue beyond what topical application alone achieves
Study Design
In vivo diabetic wound healing study using streptozotocin-induced diabetic rats. Skin-adaptive films with KPV-loaded microneedles were applied to standardized full-thickness wounds. Controls included blank films, free KPV solution, and untreated wounds. Outcomes measured included wound closure rate, histological analysis, inflammatory marker quantification, and collagen deposition over a multi-week observation period.
Limitations
- Animal model; diabetic wound healing in rats differs from human diabetic ulcer pathophysiology
- Single formulation tested; optimal KPV dose and release kinetics not fully characterized
- No comparison with standard diabetic wound care interventions
- Long-term safety and biocompatibility of the microneedle film not assessed beyond study duration
Clinical Relevance
This study extends KPV's therapeutic potential beyond gastrointestinal inflammation into dermatological wound healing, particularly in the challenging context of diabetic wounds where chronic inflammation impairs healing. The smart-release delivery approach addresses a key translational challenge for peptide therapeutics. While the specific delivery platform is investigational, the findings support KPV's broader anti-inflammatory and tissue-repair properties relevant to wound healing applications.
Related
#research #animal-in-vivo #evidence-level-V